Serum Somatomedin/Insulin-Like Growth Factor (IGF) and IGF Carrier Levels in Patients with Cushing's Syndrome or Receiving Glucocorticoid Therapy*
- 1 May 1982
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 54 (5) , 885-892
- https://doi.org/10.1210/jcem-54-5-885
Abstract
Serum levels of somatomedin (SM)/insulin-like growth factor (IGF) and IGF carrier (IGF CP) have been determined in 49 patients with Cushing's syndrome before and/or after treatment and in 11 subjects under glucocorticoid therapy. Serum samples were gel filtered in acetic acid in order to separate IGFs from their carriers. IGF content was measured by a competitive protein-binding assay using the specific IGF CP produced by rat liver in culture and human IGF ([125I]IGF I as tracer and a partially purified IGF preparation as standard). IGF CP concentration was assessed in terms of IGF CP binding to labeled IGF, compared to a reference IGF CP preparation obtained from human serum. Results are expressed in comparison with a pool of normal adult serum arbitrarily assigned values of 1 U IGF and 1 U IGF CP per milliliter. The mean IGF level for 39 untreated patients with Cushing's syndrome was 0.99 ± 0.06 (SEM) U/ml, which does not differ from normal adult values (1.05 ± 0.03). Nevertheless, 9 of these patients had subnormal values. For the 14 children or adolescents included in this group, the values observed fell within the range of the controls of the same age, although the growth rate determined for 10 of these patients averaged 1.4 cm/yr. The mean IGF CP level for the untreated patients was 0.78 ± 0.64 U/ml, which is significantly lower than that ol controls. (1.03 ± 0.05; P ¼ 0.001). No correlation was found between IGF or IGF CP levels and parameters reflecting the severity of the hypercortisolism. In the 23 patients investigated after treatment, IGF and IGF CP levels fell within the range of normal values. For the 11 subjects under glucocorticoid therapy the mean IGF and IGF CP levels were no different from control values. Sulfation assays were carried out on the same serum samples as those used for the IGF determinations in 21 of the untreated patients with Cushing's syndrome. The mean SM activity (0.65± 0.06 U/ml) was significantly lower than that of controls (0.91 ± 0.04; P ¼ 0.001), which suggests that factors other than IGF are responsible for the depressed SM activity. The conclusion that can be drawn from these findings is that the stunted growth associated with hypercortisolism cannot be attributed to an IGF deficiency. (J Clin Endocrinol Metab54: 885, 1982)Keywords
This publication has 19 references indexed in Scilit:
- Corticosteroids and GrowthNew England Journal of Medicine, 1976
- Cartilage Sulfation and Serum Somatomedin in Rats During and After Cortisone-Induced Growth ArrestEndocrinology, 1976
- Plasma growth hormone concentration in corticosteroid-treated childrenJournal of Clinical Investigation, 1968
- Metabolic effects of human growth hormone in corticosteroid-treated childrenJournal of Clinical Investigation, 1968
- GROWTH HORMONE STUDIES IN CUSHINGʼS SYNDROMEThe Lancet Healthy Longevity, 1966
- Effect of Cortisol on the Synthesis of Chondroitin Sulphate by Embryonic CartilageNature, 1966
- Antagonism by Cortisone of the Linear Growth Induced in Hypopituitary Patients and Hypophysectomized Rats by Human Growth Hormone1Journal of Clinical Endocrinology & Metabolism, 1965
- Human Growth HormoneNew England Journal of Medicine, 1964
- CONVERSION OF PROLINE-U-C14 TO LABELED HYDROXYPROLINE BY RAT CARTILAGE IN VITRO - EFFECTS OF HYPOPHYSECTOMY, GROWTH HORMONE, AND CORTISOL1962
- Effects of Prolonged Cortisone Therapy on the Statural Growth, Skeletal Maturation and Metabolic Status of ChildrenNew England Journal of Medicine, 1956